Biblio
Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial. Lancet Haematol. 2024;11(2):e101-e113.
Genomic Classification and Individualized Prognosis in Multiple Myeloma. J Clin Oncol. 2024:JCO2301277.
.